| Detailed information |
|---|
| CancerLivER ID | 2556 |
| Biomarker | VAMP2, ALDH3A2, DPP4, CCL3, HAPLN1, MAN2B1, RBPMS, ACSL6, ITPR2, PLEKHM2, RNF115, CIC, CALR, CENPN |
| Biomarker Name/Symbol (given in Publication) | VAMP2, ALDH3A2, DPP4, CCL3, HAPLN1, MAN2B1, RBPMS, ACSL6, ITPR2, PLEKHM2, RNF115, CIC, CALR, CENPN |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential marker for HCV cirrhosis progression to HCV-HCC; but not validated on independent dataset |
| Experimental Condition | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed gene |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 19861515 |
| Type of Biomarker | Prognostic |
| Pathway | Incretin synthesis, secretion, and inactivation and Peptide hormone metabolism, Uptake and actions of bacterial toxins and Insulin-mediated glucose transport, Beta-Adrenergic Signaling |
| Cohort | 16 cirrhotic tissues from patients with HCV plus hepatocellular carcinoma and 47 cirrhotic tissues from HCV-positive patients without HCC; |
| Sensitivity | 68.80% |
| Specificity | 97.90% |
| Accuracy | 90.50% |
| AUC | NA |
| Disease | HCC and CHC (Chronic hepatitis C) |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |